Overview
Intestinal botulism (also known as intestinal toxemia botulism) is a rare infectious disease caused by the colonization of the gastrointestinal tract by Clostridium botulinum (or, less commonly, other botulinum toxin-producing Clostridium species), which produces botulinum neurotoxin in situ within the intestinal lumen. Unlike foodborne botulism, where preformed toxin is ingested, intestinal botulism involves the germination of ingested spores and subsequent toxin production within the gut. The most well-known form is infant botulism, which occurs in children typically under 12 months of age, but intestinal botulism can also rarely affect adults, particularly those with altered gastrointestinal anatomy, flora, or function (e.g., due to surgery, inflammatory bowel disease, or antibiotic use). The disease primarily affects the nervous system through the action of botulinum toxin, which blocks acetylcholine release at neuromuscular junctions, leading to descending flaccid paralysis. Key symptoms include constipation (often the earliest sign), poor feeding, weak cry, diminished muscle tone (hypotonia or "floppy baby" in infants), progressive weakness, difficulty swallowing (dysphagia), ptosis, sluggish pupillary reflexes, and in severe cases, respiratory failure requiring mechanical ventilation. In adults, symptoms are similar and may include blurred vision, slurred speech, dry mouth, and generalized weakness. Treatment is primarily supportive, including nutritional support, airway management, and mechanical ventilation when necessary. For infant botulism, human-derived botulism immune globulin intravenous (BIG-IV, marketed as BabyBIG®) is the standard specific treatment and has been shown to significantly reduce hospital stay and disease severity. For adult intestinal botulism, equine-derived botulinum antitoxin may be administered. Antibiotics directed against Clostridium are generally avoided as they may cause bacterial lysis and paradoxical toxin release. Most patients recover fully with appropriate supportive care, though recovery can take weeks to months as new nerve terminals must regenerate.
Also known as:
Clinical phenotype terms— hover any for plain English:
Sporadic
Usually appears on its own, not inherited from a parent
Variable
Can begin at different ages, from infancy through adulthood
Treatments
No FDA-approved treatments are currently listed for Intestinal botulism.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Intestinal botulism at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Intestinal botulism.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Intestinal botulism.
Community
No community posts yet. Be the first to share your experience with Intestinal botulism.
Start the conversation →Latest news about Intestinal botulism
No recent news articles for Intestinal botulism.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Intestinal botulism
What is Intestinal botulism?
Intestinal botulism (also known as intestinal toxemia botulism) is a rare infectious disease caused by the colonization of the gastrointestinal tract by Clostridium botulinum (or, less commonly, other botulinum toxin-producing Clostridium species), which produces botulinum neurotoxin in situ within the intestinal lumen. Unlike foodborne botulism, where preformed toxin is ingested, intestinal botulism involves the germination of ingested spores and subsequent toxin production within the gut. The most well-known form is infant botulism, which occurs in children typically under 12 months of age,
How is Intestinal botulism inherited?
Intestinal botulism follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.